At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 89 enrolled
Drug / intervention
Fixed Dose Etoricoxib + Betamethasone +1 moredrug
Likely dose
Fixed Dose Etoricoxib + Betamethasone 90 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety Study of the Etoricoxib/Betamethasone Combination Compared With Etoricoxib for the Treatment of Patients Diagnosed With an Acute Episode of Bursitis, Tendinitis, or Synovitis of the Shoulder, Elbow, Knee, or Ankle
In Brief
A Phase 3 clinical trial evaluating Fixed Dose Etoricoxib + Betamethasone and Monotherapy Etoricoxib for Bursitis and 2 related conditions. Completed, enrolled 89 participants across 1 site.
Detailed Summary
Phase III, multicenter, prospective, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of a fixed-dose combination of etoricoxib/betamethasone compared with etoricoxib alone in patients with an acute episode of bursitis, tendinitis, or synovitis affecting the shoulder, elbow, knee, or ankle.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBursitis, Tendinitis, Synovitis
CountriesMexico
Collaborators--
Timeline
Phase 3CompletedFinished
2026
Enrollment StartMay 2025
Primary CompletionAug 2025
Study CompletionNov 2025
First PostedJan 2026
TodayJul 2026
First PostedJan 8, 2026
Enrollment StartMay 14, 2025
Primary CompletionAug 20, 2025
Study CompletionNov 19, 2025
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6 months ago
Interventions
Fixed Dose Etoricoxib + Betamethasonedrug
One tablet of 90 mg / 0.25 mg a day, for 14 days
Monotherapy Etoricoxibdrug
One tablet aog 90 mg a day, for 14 days